Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib

    November 2024 in “ Pediatric Dermatology ”
    Carli D. Needle, Lu Yin, Trevor K. Young … Vikash S. Oza
    Studysummary This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 2

    1. IL-36γ Drives Skin Toxicity Induced by EGFR/MEK Inhibition and Commensal Cutibacterium Acnes ˜The œJournal of clinical investigation/˜The œjournal of clinical investigation · 2019
    2. Cutaneous Reactions to Targeted Therapies in Children with CNS Tumors: A Cross-Sectional Study Pediatric Blood & Cancer · 2019

    Related research 1

    1. Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib Pediatric Dermatology · 2024